Brief: Cambium Bio Says FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol
25/02/2025 05:09
Feb 25 (Reuters) - Cambium Bio Ltd CMB.AX :
* FDA APPROVES ELATE OCULAR PHASE 3 CLINICAL TRIAL PROTOCOL
Further company coverage: CMB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cambium Bio
See all newsAustralia's Cambium Bio hits near three-month high on share placement at premium
Brief: Cambium Bio Appoints Olga Smejkalova As Company Secretary
Australia's Cambium Bio gains after premium share placement
Brief: Cambium Bio Raises A$1 MLN At A$0.48 Per Share
Brief: Cambium Bio Receives A$2.4 Million Investment From Zheng Yang Biomedical Technology